Orthopedia Stock Price, News & Analysis

OrthoPediatrics (NASDAQ: KIDS) has announced the expansion of its Trauma and Deformity portfolio with the 3P™ Pediatric Plating Platform™ Hip System, marking the company's 5th FDA approval in 2025. This innovative plate and screw platform aims to modernize trauma and deformity correction treatment in lower extremities.

The beta launch of 3P Hip will be followed by 3P Small/Mini in early 2026, with additional systems planned for future release. This initiative represents one of the company's largest product developments in its Trauma and Deformity division, aimed at creating the most comprehensive modern plating portfolio in pediatric orthopedic history.

OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced it will release its first quarter 2025 financial results on May 7, 2025, after market close. The company will host a conference call the same day at 4:30 p.m. ET to discuss the results.

Investors can access both the live and archived webcast of the earnings call through the Events & Presentations section of the company's website at www.orthopediatrics.com. The webcast recording will remain available for at least 90 days following the event.

OrthoPediatrics (Nasdaq: KIDS) has announced the U.S. launch of the VerteGlide Spinal Growth Guidance System, marking their 80th system for treating pediatric musculoskeletal conditions. The system, recently FDA-cleared, is designed to treat Early Onset Scoliosis (EOS) in children under 10 years old who often experience pulmonary and digestive dysfunction.

The VerteGlide system aims to correct deformity while minimizing repeat surgeries until skeletal maturity. Initial surgeries are expected to begin at select children's centers during summer 2025. The technology was developed in partnership with pediatric orthopedic surgeons Dr. Richard McCarthy and Dr. Scott Luhmann, utilizing Shilla™ technology licensed from Medtronic.

OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's leadership team, including President & CEO Dave Bailey and COO/CFO Fred Hite, will engage in a fireside chat during the conference.

Investors and interested parties can access the audio webcast of the discussion through OrthoPediatrics' investor relations website at http://ir.orthopediatrics.com, with a replay option available after the event.

OrthoPediatrics (Nasdaq: KIDS) has been named one of the 2025 Best Places to Work in Indiana for the 9th time by the Indiana Chamber of Commerce. The pediatric orthopedics-focused company joins 150 other organizations from over 20 industries across the state in this 20th edition of the recognition program.

Company President & CEO David Bailey emphasized their commitment to fostering an engaging and inclusive culture, highlighting continuous investments in employee development and meaningful career experiences. The recognition reflects the company's success in building a positive workplace environment focused on helping children.

Indiana Chamber President Vanessa Green Sinders noted the program's importance in evaluating workplace culture amid intense talent competition. The final rankings will be revealed at an awards ceremony on April 30th, 2025, followed by publication in the Chamber's BizVoice® magazine.

OrthoPediatrics (Nasdaq: KIDS) has announced its partnership with the Crossroads Pediatric Device Consortium (CPDC), a multi-institutional initiative focused on accelerating pediatric medical device development. The consortium includes Purdue University's Weldon School of Biomedical Engineering, the Indiana University School of Medicine's Department of Pediatrics, and Cook Medical.

This collaboration aims to strengthen the consortium's capabilities in developing and commercializing pediatric medical devices, particularly in orthopedics. The partnership leverages OrthoPediatrics' specialized expertise in pediatric orthopedics to enhance the consortium's innovative potential.

The CPDC's distinctive model integrates major medical device companies to streamline product development, regulatory navigation, and commercialization processes, ensuring efficient transition of pediatric medical innovations from concept to market.

OrthoPediatrics (NASDAQ: KIDS) reported strong financial results for Q4 and full year 2024. The company achieved record annual revenue of $204.7 million, up 38% from 2023, with domestic revenue increasing 45% and international revenue growing 15%.

Q4 2024 highlights include total revenue of $52.7 million, a 40% increase year-over-year, and adjusted EBITDA of $3.0 million, more than double compared to Q4 2023. The company helped over 34,000 children in Q4 and approximately 138,000 for the full year.

Key segment performance for 2024:

• Trauma and Deformity revenue: $145.1 million (+36%)
• Scoliosis revenue: $55.2 million (+45%)
• Sports Medicine/Other: $4.4 million (+11%)

For 2025, OrthoPediatrics projects revenue between $235.0-242.0 million, representing 15-18% growth, and expects adjusted EBITDA of $15.0-17.0 million.

OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.

Investors can access the conference call through a live and archived webcast available on the company's website at www.orthopediatrics.com in the Events & Presentations section of the Investors page. The webcast will remain available for replay for at least 90 days following the event.

OrthoPediatrics Corp. (NASDAQ: KIDS) has announced a distribution agreement with Thrive Orthopedics through its OrthoPediatrics Specialty Bracing (OPSB) division. The agreement covers three pediatric orthotic solutions:

1. The F3 Hero Pediatric AFO: A carbon fiber ankle foot orthosis for children with walking challenges due to cerebral palsy, spina bifida, or chemotherapy-related foot drop.

2. The TruStretch Pediatric Equinus Brace®: An above-the-knee brace for stretching gastroc-soleus muscles in children with equinus deformity.

3. The Thrive® Pediatric X-Glide Carbon Fiber Insoles: Available in rigid and flexible styles as lightweight gait training tools.